Results 311 to 320 of about 2,123,606 (402)

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Postoperative adjuvant immunotherapy and molecular targeted therapy for patients of hepatocellular carcinoma with portal vein tumor thrombus after hepatectomy: a propensity score matching study. [PDF]

Front Surg
Zhou J, Xiong H, Zhang Z, Chen D, Wang W, Zhou C, Wu B.   +6 more
europepmc   +1 more source

Progress of molecular targeted therapy for head and neck cancer in clinical aspects. [PDF]

Mol Biomed, 2021
Nakano K.
europepmc   +1 more source

Targeted Molecular Strategies for Cancer Therapy Based on the Blockade of Oncogenic Pathways in Human Tumor Cells

, 2007
Kei‐ichi Ozaki
openalex   +2 more sources

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer. [PDF]

Acta Pharmacol Sin, 2023
Zhao ZT, Wang J, Fang L, Qian XD, Cai Y, Cao HQ, Wang GR, He ML, Jiang YY, Wang DG, Li YP.   +10 more
europepmc   +1 more source

How can proteomics help in the development of molecularly targeted therapy of cancer?

, 2007
Heinrich Röder
openalex   +1 more source

The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy [PDF]

, 2009
Yong Lin, Lang Bai, Wenjie Chen, Shanling Xu   +3 more
openalex   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study. [PDF]

Cancers (Basel), 2022
Iinuma K, Kameyama K, Taniguchi T, Kawada K, Ishida T, Takagi K, Nagai S, Enomoto T, Tomioka M, Kawase M, Takeuchi S, Kato D, Takai M, Nakane K, Koie T.   +14 more
europepmc   +1 more source